翰宇藥業(300199.SZ):擬受讓中國科學院微生物研究所“一種抗新型冠狀病毒的多肽及其應用”中6條多肽序列的全球獨佔許可權
格隆匯11月14日丨翰宇藥業(300199.SZ)公佈,公司為進一步履行企業社會責任,落實公司仿創結合戰略,加快創新藥佈局,增強公司核心競爭力,助力當前新型冠狀病毒疫情防控,基於近一年來公司與中國科學院微生物研究所在多肽新冠藥物的技術交流與合作,雙方擬合作開發新型冠狀病毒多肽鼻噴劑藥物,其中中國科學院微生物研究所擬將“一種抗新型冠狀病毒的多肽及其應用”的專利申請技術(專利申請號:202110939740.1)中6條多肽序列以全球獨佔許可方式許可給翰宇藥業,項目總金額6500萬元。
公司於2021年11月12日召開第四屆董事會第三十七會議審議通過《關於與中國科學院微生物研究所簽署技術轉讓合同的議案》,董事會同意公司受讓中國科學院微生物研究所“一種抗新型冠狀病毒的多肽及其應用”中6條多肽序列的全球獨佔許可權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.